Feasibility of post-operative enteral feeding using a nasojejunal tube in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Royal Prince Alfred Hospital0 个研究点目标入组 20 人开始时间: 2021年11月17日最近更新: 2021年11月22日

适应症

试验速览

暂无简介。

•Patients undergoing CRS and HIPEC in the same procedure for peritoneal surface malignancy with a cytoreduction score of 0-1.
•Over 18 years.
•For Intervention Patients:
•Able to provide informed consent.
•Ineligible or unwilling to participate in the PRIORITY Trial. The PRIORITY trial is another research study being undertaken in this patient group at the same hospital. This study has similar research outcomes and participation in both trials may confound the study outcomes. Therefore it has been decided that participants can only participate in one trial.
•For case-matched controls
•The database will be searched for historical patients that match the intervention patients in terms of:
•Tumour Type
•Age +/- 5 years
•Peritoneal Cancer Index (PCI) +/- 5
•If no match can be found using this criteria, parameters will be expanded to Age +/-10 and PCI +/-10.

•Patients less than 18 years of age.
•Patients not scheduled for, or who do not receive both CRS and HIPEC in the same procedure.
•Patients unable to provide consent.
•Patients planned to receive a surgically placed jejunostomy as part of CRS and HIPEC.
•Patients undergoing CRS and HIPEC for Ovarian Cancer due to recruitment to the HYNOVA trial and the potential of receiving alternative HIPEC treatment.
•Recruitment to the PRIORITY Trial.

发起方